Feedback / Questions
elritercept (KER-050) - Takeda
Elritercept: Regulatory filing for 2L anemia-associated MDS in FY2028-FY2029
(Takeda)
-
Jul 31, 2026 -
Q1 FY2026 Results
Filing
•
Hematological Malignancies • Myelodysplastic Syndrome • Myeloproliferative Neoplasm • Oncology
https://assets-dam.takeda.com/image/upload/v1785376796/Global/Investor/Financial-Results/FY2026/Q1/qr2026_q1_p01_en.pdf
Jul 31, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious